Drug Search Results
More Filters [+]

9MW2921

Alternative Names: 9MW2921
Latest Update: 2024-07-16
Latest Update Note: News Article

Product Description

9MW2921 is a next generation Antibody-Drug Conjugate (ADC) developed by Mabwell based on IDDC™ (Interchain-Disulfide Drug Conjugate) platform for the treatment of solid tumors. It is an innovative antibody molecule linked to a novel payload (TOP1i) by a novel linker with fully autonomous intellectual property right. When 9MW2921 enters into the body, it can specifically bind to antigens on the cell membrane surface, be internalized and trafficked to the lysosome, release cytotoxic drug and induce the apoptosis of tumor cells. (Sourced from: https://www.mabwell.com/en/news_info/id-93.html)

Mechanisms of Action: TOP1 Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Mabwell (Shanghai) Bioscience
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for 9MW2921

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

9MW2921-2023-CP101

P2

Recruiting

Oncology Solid Tumor Unspecified

2026-09-01

57%

Recent News Events